Skip to main content
Premium Trial:

Request an Annual Quote

Third Wave's Shares Rise 11 Percent Following European OK for HPV Test

NEW YORK (GenomeWeb News) – Shares of Third Wave Technologies rose nearly 11 percent yesterday after the firm said that European regulatory authorities granted the CE Mark for the firm’s molecular diagnostic test for human papillomavirus.
The clearance from the European Union gives the company the green light to sell the test, which detects 14 high-risk types of HPV and is used in screening for cervical cancer, in EU member nations and in other nations that recognize the CE mark.
The company said it expects to market the test in Europe in January 2008.
Third Wave’s test will join several other molecular diagnostic tests for HPV on the European market, including assays sold by Qiagen, Roche, Biotools, and bioMérieux. Qiagen is the only firm to have both European and US clearance to sell its HPV molecular diagnostic test.

The Scan

Plan Rebuffed

The Associated Press reports China has rejected the World Health Organization's proposal to include the lab-leak theory in the next phase of its investigation into the origins of SARS-CoV-2.

Opossum Change

Researchers from Riken have used CRISPR to edit marsupial genomes, as Technology Review reports.

In the Ice

Cosmos magazine reports that researchers have uncovered more than two dozen ancient viruses in a Tibetan glacier.

Nature Papers Present Method to Uncover Differential RNA Modifications, Neutrophils in Innate Immune Response

In Nature this week: computational approach to identifying differential RNA modifications, and more.